1. HDAC1 regulates the chemosensitivity of laryngeal carcinoma cells via modulation of interleukin-8 expression.
- Author
-
Ding S, Tang Z, Jiang Y, Luo P, Qing B, Wei Y, Zhang S, and Tang R
- Subjects
- 3' Untranslated Regions, Cell Line, Tumor, Cell Proliferation drug effects, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic, Histone Deacetylase 1 genetics, Humans, Interleukin-8 genetics, Laryngeal Neoplasms enzymology, Laryngeal Neoplasms pathology, Signal Transduction, Squamous Cell Carcinoma of Head and Neck enzymology, Squamous Cell Carcinoma of Head and Neck pathology, Antineoplastic Agents pharmacology, Cisplatin pharmacology, Fluorouracil pharmacology, Histone Deacetylase 1 metabolism, Interleukin-8 metabolism, Laryngeal Neoplasms drug therapy, Squamous Cell Carcinoma of Head and Neck drug therapy
- Abstract
Chemotherapies such as 5-fluorouracil (5-FU) and cisplatin (CDDP) have been widely used to treat laryngeal squamous cell carcinoma (LSCC), the second most common head and neck squamous cell carcinoma. However, chemoresistance seriously impairs chemotherapeutic efficacy. Our present study reveals that 5-FU and CDDP treatment increase the expression of histone deacetylase 1 (HDAC1) in LSCC cells. Consistently, increased levels of HDAC1 are observed in chemoresistant cells. Knockdown of HDAC1 significantly restores the sensitivity of LSCC cells, as HDAC1 increases the expression of interleukin-8 (IL-8), which is essential for LSCC chemoresistance. Mechanistically, HDAC1 directly initiates the transcription of IL-8 though binding to its promoter. Simultaneously, si-HDAC1 increases the levels of miR-93, which binds to the 3'UTR of IL-8 mRNA to trigger its degradation. In summary, the HDAC1/IL-8 axis can confer chemotherapeutic resistance to LSCC cells., (Copyright © 2021 Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF